retatrutide phase 2 weight loss Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Delivers Significant Hemoglobin A1C

Business travel Frequent business travelers benefit most from a compact, professional-looking travel case that does not draw attention in meeting rooms or client offices

Univariate analysis provides a straightforward assessment of individual features, highlighting those with significant differences between groups

1 Cardiovascular disease (CVD) is the most prominent cause of morbidity and mortality among patients with T2D

Because obesity can drive chronic inflammation, raise insulin levels, and alter the metabolic environment around tumors, researchers are now asking whether GLP-1 drugs may help change those conditions in ways that could affect cancer risk or outcomes, not just body weight

The glucose stimulation index was calculated as the ratio of insulin concentration at 15, 30, and 60 min after intraperitoneal glucose injection to the basal insulin concentration

P38 Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial -Endorphin Expression